The placebo solution will contain the same sterile aqueous buffered solution as the test product but will not contain SHP647

3 trials

Sponsors

Shire Human Genetic Therapies, Inc. ("Shire")

Conditions

Crohn Disease CDModerate to Severe Crohn Disease CDModerate to severe Ulcerative Colitis Ulcerative Colitis

Phase 3

A study of the Efficacy and Safety of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis

Active, not recruitingLBCTR2019090238

Shire Human Genetic Therapies, Inc. ("Shire")Moderate to severe Ulcerative Colitis Ulcerative Colitis

Start: 2019-11-01Target: 12Updated: 2026-02-02

A study of the Efficacy and Safety of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306)

Active, not recruitingLBCTR2019090248

Shire Human Genetic Therapies, Inc. ("Shire")Crohn Disease CD

Start: 2019-11-30Target: 6Updated: 2026-02-02

A study on the Efficacy and Safety of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307)

Active, not recruitingLBCTR2019090265

Shire Human Genetic Therapies, Inc. ("Shire")Moderate to Severe Crohn Disease CD

Start: 2020-03-30Target: 4Updated: 2026-02-02